Answers are grounded in this paper and cite their sources.
Glyco-engineering of expression platforms is increasingly recognized as an important strategy to improve biopharmaceuticals. A better understanding and control of the factors leading to glycan heterogeneity will allow simplified production of recombinant glycoprotein therapeutics with less variation in terms of glycosylation. Further technological advances will have a major impact on manufacturing processes and may provide a completely new class of glycoprotein therapeutics with customized functions.
No takes yet. Share an insight, caveat, or question.
Dicker et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: